Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Anavex Life Sciences Corp AVXL

Healthcare Biotechnology
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of... see more

Recent & Breaking News (NDAQ:AVXL)

Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension

GlobeNewswire January 16, 2018

42 Biggest Movers From Yesterday

Benzinga.com  December 12, 2017

30 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  December 11, 2017

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

GlobeNewswire December 11, 2017

Anavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor

GlobeNewswire November 21, 2017

Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC

GlobeNewswire November 8, 2017

Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting

GlobeNewswire November 4, 2017

Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference

GlobeNewswire October 30, 2017

Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017

GlobeNewswire October 27, 2017

Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates

Benzinga.com  October 12, 2017

Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

GlobeNewswire October 12, 2017

Anavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GlobeNewswire September 21, 2017

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73

GlobeNewswire September 5, 2017

Anavex Reports Fiscal Third Quarter 2017 Financial Results

GlobeNewswire August 7, 2017

Anavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board

GlobeNewswire July 20, 2017

Anavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference

GlobeNewswire June 5, 2017

Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented at Antiepileptic Drug Trials XIV 2017 Conference

GlobeNewswire May 22, 2017

Anavex Reports Fiscal Second Quarter 2017 Financial Results

GlobeNewswire May 10, 2017

Research Reports Initiation on Biotech Stocks -- Egalet, Argos Therapeutics, Alder Biopharma, and Anavex Life Sciences

PR Newswire May 4, 2017

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs

GlobeNewswire May 1, 2017